AUA
  • Program
  • Register
  • Meeting Coverage
  • Guidelines
  • Industry Highlights
  • Science & Technology Hall
Topics
  • Meeting Coverage
  • Guidelines
  • Industry Highlights
  • Science & Technology Hall
Resources
  • Program
  • Register
Twitter X icon Facebook iconInstagram iconYouTube iconLinkedIn icon
May 05, 2026

The great ablation debate

Cryoablation, microwave, SBRT and histotripsy go head-to-head as specialists argue what works best—and for whom.


Professional headshot of a man wearing glasses and business attire against a blue background
Jeffrey A. Cadeddu, MD, FRCS

Minimally invasive tumor ablation techniques are gaining increasing attention as alternatives to surgery for patients with early‑stage kidney cancer, and urologists are set to debate the latest options at the 2026 AUA Annual Meeting.

According to Jeffrey A. Cadeddu, MD, FRCS, moderator of the session Survivor Debate: Best Ablation Modality for Small Renal Masses, today’s many ablation therapies offer patients additional treatment choices, particularly for those with small, stage‑one renal tumors. Dr. Cadeddu is a professor of urology at the University of Texas Southwestern Medical School in Dallas. Although surgery remains the standard approach, he said, ablation techniques offer a less invasive option with lower risk and faster recovery. 

“Ablation isn’t necessarily preferred over surgery—it’s another option,” Dr. Cadeddu said. “The advantage is that it avoids many of the risks associated with surgery, including bleeding, anesthesia, kidney injury and prolonged recovery.” 

One of the key advantages of ablation is that it reduces morbidity, Dr. Cadeddu said. Even with robotic surgery, there is a risk of bleeding and kidney injury as well as those risks associated with anesthesia. Often, ablations are performed as outpatient procedures. They generally do not require a hospital stay, and some of the technologies that will be debated during the session do not require anesthesia, he said.

However, ablation is not appropriate for every patient. According to Dr. Cadeddu, eligibility depends largely on tumor size and location. The procedures discussed at the session are intended for tumors smaller than three centimeters, all of which are classified as stage‑one cancers. 

One trade‑off with ablation, he said, is a small risk of incomplete treatment or recurrence, because the tumor is destroyed rather than surgically removed. Dr. Cadeddu noted that incomplete treatment or recurrence rates generally range from 5% to 10%, depending on tumor characteristics and the technology used.

“Many surgeons would have a bias against ablation because of the risk of recurrence,” Dr. Cadeddu said. “But, if the cancer returns, you can always do surgery or, better yet, you can do another ablation with success rates, then matching surgery.”

The session will feature a debate among specialists representing four ablation modalities: cryoablation, microwave ablation, stereotactic body radiation therapy (SBRT) and histotripsy, an emerging ultrasound‑based technique. Although cryoablation and microwave ablation are well-established, needle-based approaches, SBRT and histotripsy are newer, fully noninvasive technologies that require no incisions or needles, Dr. Cadeddu said. 

During the session, speakers will evaluate a clinical case and argue why their modality is best suited for treatment. Audience members will participate by voting, eliminating options and, ultimately, selecting a preferred approach based on the evidence presented. 

Dr. Cadeddu said the debate reflects a broader shift in cancer care toward offering patients multiple effective treatment options tailored to their needs.

Interesting Stories
Unique formulation of YONSA® (abiraterone acetate) makes it different
Sponsored by Sun Pharma
Unique formulation of YONSA® (abiraterone acetate) makes it different
Find your next big break at AUA2026
Sponsored by AUA
Find your next big break at AUA2026
AUA means business: AUA Annual Business Meeting is May 18
Sponsored by AUA
AUA means business: AUA Annual Business Meeting is May 18
Book your AUA2026 housing now
Sponsored by AUA
Book your AUA2026 housing now
More Content
Professional headshot of a man wearing glasses, pink shirt, and burgundy bow tie
Previews
Rethinking cancer detection
May 05, 2026
Pain scale gauge showing emotion faces ranging from happy green (no pain) to crying red (severe pain) with numbered indicator
Previews
The big shift
May 05, 2026
Professionals demonstrate robotic arm technology at hands-on event with participants wearing blue gloves
Previews
AUA2026 amps up hands-on skills training
May 05, 2026
Glowing abstract sphere with horns and luminous network pattern on dark background
Previews
Bladder transplantation changes the game
Apr 21, 2026
Male surgeon in blue surgical cap and scrubs smiling at camera in hospital corridor
Previews
Scanning the best options
Apr 21, 2026
Professional headshot of a man in navy suit and striped tie with organizational pin
Previews
Separating myth from measurable outcomes
Apr 21, 2026
Illustration of a person working at a computer with robotic arms assembling digital technology above
Previews
AI: Your new interoperative partner
Apr 21, 2026
Surgical team performing minimally invasive procedure in operating room with imaging displays
Previews
Enhancing surgical vision
Apr 07, 2026
Professional headshot of a man wearing glasses, light blue shirt, and dark blazer with purple tie
Previews
To cut or not to cut? Bladder preservation takes center stage
Apr 07, 2026
Professional headshot of a man wearing glasses and business attire against a blue background
Previews
When BPH treatments fail
Apr 07, 2026
Abstract white mesh wave pattern flowing across dark blue background with smooth, undulating curves
Previews
A scalpel-free future for kidney tumors?
Apr 07, 2026
Medical team analyzing bladder anatomy and research data on digital screen
AUA2025
P2s spotlight groundbreaking clinical trials
Apr 15, 2025
AUA
Twitter X icon Facebook iconInstagram iconYouTube iconLinkedIn icon
© 2026 Ascend Media. All rights reserved.